HER2newC apoptosis inducer
Early Breast Cancer (neoadjuvant)
Pre-clinicalActive
Key Facts
About IcanoMAB
IcanoMAB is a German biotech developing a portfolio of canonical signaling monoclonal antibodies derived from a proprietary rabbit-based discovery platform. The company has secured three IND-enabling stage assets: a HER2newC apoptosis inducer for breast cancer, a CD40 agonist for immuno-oncology, and an IL-1R7 antagonist for acute inflammatory diseases like Covid-19 ARDS/CRS. Founded in 2013 by experienced pharma alumni, the private company is pre-revenue and plans to use funding to advance candidates through IND-enabling studies and seek strategic partnerships.
View full company profile